Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: Preclinical and clinical developments

Expert Opinion on Investigational Drugs

Volumn 16, Issue 12, 2007, Pages 1909-1920

  Hicks, Alexandra ^a   Monkarsh, Seth P ^a   Hoffman, Ann F ^a   Goodnow Jr , Robert ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

BLT1; BLT2; Eicosanoids; Inflammatory disease; Leukotriene B4; LTB4

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 2 (3 BENZYL 4 HYDROXYCHROMAN 7 YL) 4 TRIFLUOROMETHYLBENZOIC ACID; 5 [2 (2 CARBOXYETHYL) 3 [6 (4 METHOXYPHENYL) 5 HEXENYLOXY]PHENOXY]VALERIC ACID; 7 [3 (4 ACETYL 3 METHOXY 2 PROPYLPHENOXY)PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 CARBOXYLIC ACID; 7 [3 [2 (CYCLOPROPYLMETHYL) 3 METHOXY 4 (4 THIAZOLYL)PHENOXY]PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 CARBOXYLIC ACID; AM 103; AMELUBANT; BIIL 260; BIIL 284; BIIL 315; BIOMED 101; CELECOXIB; CISPLATIN; DW 1350; DW 1352; ETALOCIB; GEMCITABINE; INTERLEUKIN 2; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR AFFECTING AGENT; METHOTREXATE; MOXILUBANT MALEATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; ZILEUTON; NEW DRUG;

ALLERGIC DISEASE; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BEHCET DISEASE; CHEMICAL STRUCTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ENTERITIS; FATIGUE; FEVER; FRACTURE; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; KIDNEY CANCER; LIVER WEIGHT; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; PAIN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; ULCERATIVE COLITIS; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; INFLAMMATION; METABOLISM; METHODOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; INFLAMMATION; RECEPTORS, LEUKOTRIENE B4; SIGNAL TRANSDUCTION;

EID: 39549095380     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.12.1909     Document Type: Review

References (47)

1. TAGER AM, LUSTER AD: BLT1 and BLT2: the leukotriene B4 receptors. Prostaglandins Leukot. Essent. Fatty Acids (2003) 69:123-134.
2. YOKOMIZO T. IZUMI T, SHIMIZU T: Leukotriene B4: metabolism and signal transduction. Arch. Biochem. Biophys. (2001) 385(2):231-241.
3. LUNDEEN KA, SUN B, KARLSSON L, FOURIE AM: Leukotriene B4 receptors BLT1 and BLT2: expression and function in human and murine mast cells. J Immunol. (2006) 177:3439-3447.
4. DEL PRETE A, SHAO WH, MITOLA S, SANTORO G, SOZZANI S, HARIBABU B: Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood (2006) 109(2):626-631.
5. LUSTER AD, TAGER AM: T-cell trafficking in asthma: lipid mediators grease the way. Nat. Rev. Immunol. (2004) 711(4):711-724.
6. PROFITA M, SALA A, RICCOBONO L et al.: 15(S)-HETE modulates LTB4 production and neutrophil chemotaxis in chronic bronchitis. Am. J. Physiol. (2001) 279:C1249-C1258.
7. ARITA M, OHIRA T, SUN YP, ELANGOVAN S, CHIANG N, SERHAN CN: Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. (2007) 178:3912-3917.
8. MIYAHARA N, MIYAHARA S, TAKEDA K, GELFAND EW: Rote of the LTB4/BLT1 pathway in allergen-induced airway responsiveness and inflammation. Allergy Int. (2006) 55:91-97.
9. TERAWAKI K, YOKOMIZO T, NAGASE T et al.: Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J. Immunol. (2005) 175:4217-4225.
10. + T lymphocytes and leukotriene B4: novel interactions in the persistence and progression of asthma. J. Allergy Clin. Immunol. (2006) 117:577-582.
11. SHIN EH, LEE HY, BAE YS: Leukotriene B4 stimulates human monocyte-derived dendritic cell chemotaxis. Biochem. Biophys. Res. Commun. (2006) 348:606-611.
12. MARIAN E, BARALDO S, VISENTIN A et al.: Up-regulated membrane and nuclear leukotriene B4 receptors in COPD. Chest (2006) 129(6):1523-1530.
13. HAN C, HUANG H, HU M, WANG Q, GAO Y, LIU Y: Time-dependent expression of leukotriene B4 receptors in rat collagen-induced arthritis. Prostaglandins Other Lipid Mediat. (2007) 83:225-230.
14. HASHIMOTO A, ENDO H, HAYASHI I et al.: Differential expression of leukotriene B4 receptor subtypes (BIT1 and BLT2) in human synovial tissues and synovial fluid leukocytes of patients with RA. J. Rheumatol. (2003) 30(8):1712-1718.
15. SHAO WH, DEL PRETE A, BOCK CB, HARIBABU B: Targeted disruption of leukotriene B4 receptors BLT1 and BLT2: a critical role for BLT1 in collagen-induced arthritis in mice. J. Immunol. (2006) 176:6254-6261.
16. AIELLO RJ, BOURASSA PA, LINDSEY S, WENG W, FREEMAN A, SHOWELL HJ: Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler. Thromb. Vasc. Biol. (2002) 22:443-449.
17. SUBBARAO K, JALA VR, MATHIS S: Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler. Thromb. Vasc. Biol. (2004) 24:369-375.
18. HELLER EA, LIU E, TAGER AM et al.: Inhibition of atherogenesis in BIT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation (2005) 112(4):578-586.
19. AHLUWALIA N, LIN AY, TAGER AM et al.: Inhibited aortic aneurysm formation in BLT1-deficient mice. J. Immunol. (2007) 179:691-697.
20. KANDA N, WATANABE S: Leukotriene B4 enhances TNF-α-induced CCL27 production in human keratinocytes. Clin. Exp. Allergy (2007) 37:1074-1082.
21. DEVCHAND PR, KELLER H, PETERS JM et al.: The PPARα-leukotriene B4 pathway to inflammation control. Nature (1996) 384:39-43.
22. DEVCHAND PR, HIHI AK, PERROUD M, SCHLEUNING WD, SPIEGELMAN BM, WAHLI W: Chemical probes that differentially modulate peroxisome proliferator-activated receptor-α and BLTR, nuclear and cell surface receptors for LTB4. J. Biol. Chem. (1999) 274:23341-23348.
23. BIRKE FW, MEADE CJ, ANDERSKEWITZ R, SPECK GA, JENNEWEIN HM: In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B4 receptor antagonist. J. Pharm. Exp. Ther. (2001) 297(1):458-466.
24. DIAZ-GONZALEZ F, ALTEN RHE, BENSEN WG et al.: Clinical trial of a leukotriene B4 receptor antagonist, BIIL 284, in patients with RA. Am. Rheumat. Dis. (2007) 66(5):628-632.
25. ALTEN R, GROMNICA-IHLE E, POHL C et al.: Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL-284, a new long-acting LTB4 receptor antagonist, in patients with RA. Ann. Rheumat. Dis. (2004) 63(2):170-176.
26. SCHWARTZ GK, BUDMAN DR, ENDRES S et al.: Phase I and pharmacokinetic study of LY293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor and peroxisome proliferator activated receptor-γ agonist (PPARγ). Proc. Am. Soc. Clin. Oncol. (2002) 21(1):A86.
27. SAWYER JS: Leukotriene B4 receptor antagonists: recent clinical developments. Expert Opin. Investig. Drugs (1996) 5(1):73-77.
28. EVANS DJ, BARNES PJ, SPAETHE SM et al.: Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax (1996) 51(12):1178-1184.
29. MOMMERS JM, VAN ROSSUM MM, KOOIJMANS-OTERO ME, PARKER GL, VAN DE KERKHOF PCM: VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis. Br. J. Dermatol. (2000) 142:259-266.
30. DING XZ, TALAMONTI MS, BELL RH Jr, ADRIAN T: A novel anti-pancreatic cancer agent, LY293111. Anticancer Drugs (2005) 16(5):467-473.
31. JANNE PA, PAZ-ARES RODRIGUEZ L, GOTTFRIED M et al.: Randomized Phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosonoid pathway modulator, in patients with chemotherapy naive advanced non-small cell lung carcinoma. J. Clin. Oncol. (2006) 24(18 Suppl.):7024.
32. SHOWELL HJ, CONKLYN MJ, ALPERT R et al.: The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543. J. Pharm. Exp. Ther. (1998) 285:946-954.
33. YOKOMIZO T, KATO K, HAGIYA H, IZUMI T, SHIMIZU T: Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J. Biol. Chem. (2001) 276(15):12454-12459.
34. GRÖNKE L, BEEH KM, CAMERON R et al.: LTB 019A, a leukotriene B4 receptor antagonist, has no effect on the levels of neutrophils, mMPO, IL-8 and TNF-α in induced sputum of COPD patients in vivo. Am. J. Respir. Crit. Care Med. (2002) 165:A598.
35. TSAI BS, VILLANI-PRICE D, KEITH RH et al.: SC-41930: an inhibitor of leukotriene B4-stimulated human neutrophil functions. Prostaglandins (1989) 38(6):655-674.
36. KEMENY L, RUZICKA T: SC-41930, a leukotriene B4 receptor antagonist, inhibits 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) binding to epidermal cells. Agents Actions (1991) 32(3-4):339-342.
37. FRETLAND DJ, WIDOMSKI D, TSAI BS et al.: Effect of the leukotriene B4 receptor antagonist SC-41930 on colonic inflammation in rat, guinea pig and rabbit. J. Pharm. Exp. Ther. (1990) 255(2):572-576.
38. PENNING TA, DJURIC SW, MIYASHIRO JM et al.: Second-generation leukotriene B4 receptor antagonists related to SC-41930: heterocyclic replacement of the methyl ketone pharmacophore. J. Med. Chem. (1995) 38(6):858-868.
39. NME digest. Drug News Persp. (2003) 16(6):387.
40. POUDEL JM, HULLOT P, VIDAL JP et al.: Synthesis and pharmacological profile of new 1,3-disubstituted cyclohexanes as leukotriene B4 receptor antagonists. Bioorg. Med. Chem. Lett. (1996) 6:2349-2354.
41. ANDO K, TSUJI E, ANDO Y et al.: Synthesis of 2, 4- snf 5-(2-alkycarbamoyl- 1-methylninyl)-7-alkyloxybenzo[b]furans and their leukotriene B4 receptor antagonistic activity. Org. Biomol. Chem. (2005) 3:2129-2139.
42. HWANG SW CHO H, KWAK J et al.: Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances Proc. Natl. Acad. Sci. USA (2000) 97:6155-6160.
43. MCHUGH D, MCMASTER RS, PERTWEE RG et al.: Novel compounds that interact with both leukotriene B4 receptors and vanilloid TRPV1 receptors J. Pharm. Exp. Ther. (2006) 316:955-965.
44. SCOW DT, LUTTERMOSER. GK, DICKERSON KS: Leukotriene inhibitors in the treatment of allergy and asthma. Am. Fam. Phys. (2007) 75:65-70.
45. RASK-MADSEN J: Leukotrienes as targets in the gut. Clin. Exp. Allergv Rev. (2001) 1(3):309-312.
46. MOY ML, DEYKIN A, REILLY JJ et al.: Zileuton improves exercise capacity in COPD. Am. J. Crit. Care Med. (2002) 165:595.
47. EVANS RB: Comparative results of leukotriene modifiers in COPD and asthma. Am. J. Crit. Care Med. (1998) 157:413.